1. Highly potent and selective chiral inhibitors of pde5: an illustration of pfeiffer's rule;Bunnage;Bioorg. Med. Chem. Lett.,2008
2. FDA's policy statement for the development of new stereoisomeric drugs. U.S. Food and Drug Administration Regulatory Guidelines;U.S. Food and Drug Administration,1992
3. Investigation of chiral active substance. European Union Guideline;European Union,1993
4. Guidelines for industry stereochemical issues in chiral drug development. Health Canada Guidelines Document;The Minister of Health,2000
5. Provisions for drug registration, Order 28;SFDA of China,2007